I thought it was vital to bring this up as I am seeing this study circulate and being used in a lot of media today concerning Brazil’s variant P.1. Most of the misinformation over Brazil’s variant P.1 appears to stem from a single, unreliable serological survey in Manaus. 🧵
We can see the media has latched on to a study which claimed Manaus had reached herd immunity due to 76% of its population being previously infected with SARS-CoV-2. The claim was based on flawed serology data- its likely they never did. We now see that any reference to Manaus is
laced with fear of reinfection, despite there being no evidence of this on a larger scale. A follow-up study that received less publicity found that their peak was more like 15% rather than 76% that was being circulated and claimed.
thelancet.com/journals/langl…
For one, this study here is solely based on modeling and has been circulating through a lot of media in Brazil as well as the UK, and data (or lack there of) unfortunately was based on a prior modeling study that was debunked (the 76% issue you see discussed above and below).
The previous study was debunked last year here by Wes Pegden. Please do be sure to read this thread in its entirety as it is extremely informative.
Thanks to the wonderful @stevebrown2856, as he states, “we can see the study hypothesizing high rates of reinfection used a modeling approach based on high fatalities and calibrated against the 76% prior attack rate, meaning it is likely flawed. The whole study falls apart with a
lower prior attack rate.” Furthermore, “the idea is that because the 1st wave in Manaus was apparently so large, the 2nd can only have occurred with significant reinfections. However, if the 1st wave was much smaller (but with high fatalities because Manaus ran out of oxygen)
the logic falls apart.” From what we are seeing, it seems the issue lies within Manaus collapse of its healthcare system during the 1st wave, making reinfection seem much more severe than it really was and a sense of false security come the 2nd wave. With new preprints today
we are seeing that P.1 is proving to be less of a threat than B.1.351 and B.1.1.7 and that the vaccines stand to be protective against this variant which can be seen here:
The point I am attempting to address is that, while a VOC, P.1 is something that is within our grasp of controlling and I just wanted everyone to be certain of the flaws of the study circulating in the media. Special thank you to @stevebrown2856, @davidbautistaqf and @guto7776.
I was up for quite some time last night sifting through studies and newspaper articles and I was tired of seeing people having to be thrown into a panic with little understanding so hopefully this helps today.
Also, so everyone understands, once again, in trying to clear up misinformation, my intentions are never to “trash” anyone’s research. I was trying to point out discrepancies that have led to a lot of misunderstandings and confusion. I’m not looking for a “gotcha” moment.

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Mac n’ Chise 🧬🦠🧫

Mac n’ Chise 🧬🦠🧫 Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @sailorrooscout

5 Mar
Studies show that a SINGLE dose of the Oxford/AstraZeneca vaccine is highly efficacious 90 days post-vaccination, a longer prime-boost interval results in higher vaccine efficacy, and protection against symptomatic COVID-19 is maintained despite a longer dosing interval. 🧵
Researchers reported the updated primary efficacy results for the Oxford–AstraZeneca ChAdOx1 nCoV-19 (AZD1222) vaccine from three single-blind, randomized controlled trials in the UK and Brazil and one double-blind study in South Africa.
thelancet.com/journals/lance…
A subsequent report, based on an interim analysis of the randomized controlled trials done in Brazil, South Africa, and the UK, suggested an overall vaccine efficacy of 70.4% (95.8% CI 54.8–80.6), with a higher efficacy of 90% (95% CI 67.4–97.0) in those who received a low dose
Read 12 tweets
3 Mar
A recent study shows Pfizer’s and Moderna’s vaccines are protective against SARS-CoV-2 variant P.1. Despite some reduction, loss of neutralizing activity was modest (2.8 & 2.2 fold) & reduction was not as striking as observed prior against B.1.351. 🧵
biorxiv.org/content/10.110…
To study this, researchers created a VSV-based SARS-CoV-2 pseudovirus with all 10 mutations of the P.1 variant (B.1.1.28 lineage) and assessed its susceptibility to neutralization by neutralizing mAbs, convalescent plasma of patients, and vaccinee sera.
For thoroughness, activity of four mAbs including REGN10987 (imdevimab), REGN10933 (casirivimab), LY-CoV555 (bamlanivimab) and CB6 (etesevimab), six NTD mAbs, convalescent plasma of patients infected in Spring of 2020, and sera of Moderna and Pfizer recipients were analyzed.
Read 10 tweets
3 Mar
Cell-mediated immunity at work! Researchers in South Africa have found it you were previously infected with 501Y.V2 (B.1.351) your antibodies are cross-reactive and thereby able to neutralize other variants of SARS-CoV-2 and prevent infection from other variants!
Their research demonstrates immune response to B.1.351 is as potent as that seen in those infected with the original variant. Furthermore, antibodies from people infected with B.1.351 are not only able to neutralize B.1.351 but variant P.1 as well!
The press conference can be found here:
Read 8 tweets
2 Mar
The importance of T-cell immunity! This study finds CD4+ and CD8+ T-cell mediated responses are minimally affected by mutations found in SARS-CoV-2 VOCs (B.1.1.7, B.1.351, & P.1.) and VOI CAL20.C! Immunity is about more than just antibodies! Let’s go! 🧵
biorxiv.org/content/10.110…
Researchers utilized convalescent plasma to directly assess TCRs from persons recovered from previous SARS-CoV-2 infections obtained before the emergence of the variants, and from recent Moderna and Pfizer vaccine recipients for their capacity to recognize peptides derived from
the ancestral reference sequence as well as the B.1.1.7, B1.351, P.1 and the CAL.20C variants. Bioinformatic analyses were utilized to predict the impact of mutations in the various variants with sets of previously reported CD4+ and CD8+ T cell epitopes derived from the ancestral
Read 14 tweets
1 Mar
Some good news for your day! The latest real-world study from Public Health England (PHE) shows that both Pfizer’s AND Oxford-AstraZeneca’s vaccines are both highly effective in reducing SARS-CoV-2 infections among older people aged 70 years and over.
khub.net/documents/1359…
Since January, protection against symptomatic COVID, 4 weeks after the first dose, ranged between 57 and 61% for one dose of Pfizer’s vaccine and between 60 and 73% for Oxford-AstraZeneca’s vaccine. Their data shows symptomatic infections in those over 70 decreasing from around 3
weeks after one dose of either vaccine. In those over 80, study data suggested a single dose of either vaccine is more than 80% effective at preventing hospitalization, around 3 to 4 weeks post immunization. Evidence also suggests Pfizer’s vaccine, leads to an 83% reduction in
Read 6 tweets
28 Feb
Guys. This is P.1. It isn’t “new” or “novel.” It has now been detected in cases in the U.K. We know the vaccines can neutralize this variant, and updated boosters should they be needed are already in development. Please don’t be alarmed. This is what viruses do, they spread.
If you’re interested in reading more about mutations and how we go about controlling these please see:
Keep in mind this study only takes into account humoral immunity and nAbs rather than cell mediated immunity as well (which I am a huge advocate for) but you can see the vaccines can neutralize P.1.
medrxiv.org/content/10.110…
Read 10 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!